Eco Animal Health Group plc (AIM: EAH), a UK-headquartered global animal health company, has announced new marketing authorisations for its flagship antibiotic Aivlosin® in Paraguay and Honduras, alongside import permits enabling accelerated market access in Saudi Arabia and Oman. The company confirmed that commercial sales of Aivlosin® have already commenced in both Saudi Arabia and Oman, leveraging existing commercial infrastructure. The expansion broadens ECO's geographic footprint for its market-leading livestock antibiotic, which is already distributed across more than 70 markets worldwide.
Key Points
- Eco Animal Health Group plc (AIM: EAH) is a leading global animal health company focused on livestock productivity and welfare
- New Aivlosin® marketing authorisations granted in Paraguay and Honduras; import permits secured for Saudi Arabia and Oman
- Commercial sales in Saudi Arabia and Oman have already begun; Saudi Arabia's poultry market is growing at 5.8% annually and accounts for over half of the region's animal health market
- Investors may be watching for further geographic authorisations and progress from ECO's R&D pipeline, including the ECOVAXXIN® MS poultry vaccine launched in the EU in July 2026
Aivlosin® Gains Four New Market Access Points Across Latin America and the Middle East
ECO Animal Health has secured regulatory approvals and import permits across four new territories for Aivlosin®, its proprietary antibiotic used to treat respiratory and intestinal diseases in pigs and poultry. Paraguay and Honduras represent ECO's continued push into Latin America, while Saudi Arabia and Oman are being accessed via special import licences, providing what the announcement describes as accelerated routes to market. The company stated that these new authorisations will largely leverage the Group's existing commercial infrastructure for Aivlosin®, potentially limiting incremental distribution costs for entry into these territories.
Saudi Arabia's 5.8% Annual Poultry Market Growth Underpins Middle East Opportunity
The announcement highlights Saudi Arabia as a commercially significant target, noting that the country's poultry market is growing at 5.8% annually and that it accounts for over half of the regional animal health market. ECO describes this as a meaningful commercial opportunity for Aivlosin®. Commercial sales in both Saudi Arabia and Oman have already begun following the import permit approvals. The Middle East expansion complements recent progress the company cited in South and South East Asia, suggesting a broader international growth strategy centred on Aivlosin® as the core revenue-generating product.
CEO David Hallas Cites Latin America Entry and R&D Pipeline Alongside Regulatory Progress
Chief Executive David Hallas noted in the announcement that the new authorisations extend ECO's reach into Latin America and establish a foothold in a key Middle East poultry market. He also referenced recent geographic progress in South and South East Asia and highlighted the company's innovative R&D pipeline as an additional growth driver. ECO's first pipeline product, ECOVAXXIN® MS — a poultry vaccine targeting Mycoplasma synoviae infection — was commercially launched in the EU in July 2026, representing ECO's self-funded move into prevention and vaccines alongside its established antibiotic business.




Please wait processing your request...